COLLEGIUM PHARMACEUTICAL INC (COLL) Fundamental Analysis & Valuation

NASDAQ:COLL • US19459J1043

37.24 USD
-0.03 (-0.08%)
Last: Mar 10, 2026, 09:45 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This COLL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Overall COLL gets a fundamental rating of 5 out of 10. We evaluated COLL against 193 industry peers in the Pharmaceuticals industry. While COLL has a great profitability rating, there are some minor concerns on its financial health. COLL is cheap, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

7

1. COLL Profitability Analysis

1.1 Basic Checks

  • In the past year COLL was profitable.
  • In the past year COLL had a positive cash flow from operations.
  • In multiple years COLL reported negative net income over the last 5 years.
  • Of the past 5 years COLL 4 years had a positive operating cash flow.
COLL Yearly Net Income VS EBIT VS OCF VS FCFCOLL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

  • COLL has a better Return On Assets (3.64%) than 84.97% of its industry peers.
  • COLL has a Return On Equity of 21.27%. This is amongst the best in the industry. COLL outperforms 91.19% of its industry peers.
  • COLL has a Return On Invested Capital of 9.10%. This is amongst the best in the industry. COLL outperforms 88.60% of its industry peers.
  • COLL had an Average Return On Invested Capital over the past 3 years of 11.08%. This is below the industry average of 13.09%.
Industry RankSector Rank
ROA 3.64%
ROE 21.27%
ROIC 9.1%
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
COLL Yearly ROA, ROE, ROICCOLL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

  • COLL's Profit Margin of 7.72% is amongst the best of the industry. COLL outperforms 83.94% of its industry peers.
  • In the last couple of years the Profit Margin of COLL has declined.
  • With an excellent Operating Margin value of 20.74%, COLL belongs to the best of the industry, outperforming 88.08% of the companies in the same industry.
  • COLL's Operating Margin has improved in the last couple of years.
  • COLL has a Gross Margin of 57.22%. This is in the better half of the industry: COLL outperforms 68.39% of its industry peers.
  • COLL's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 20.74%
PM (TTM) 7.72%
GM 57.22%
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
COLL Yearly Profit, Operating, Gross MarginsCOLL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. COLL Health Analysis

2.1 Basic Checks

  • COLL has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • COLL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
COLL Yearly Shares OutstandingCOLL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
COLL Yearly Total Debt VS Total AssetsCOLL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • COLL has an Altman-Z score of 1.34. This is a bad value and indicates that COLL is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of COLL (1.34) is comparable to the rest of the industry.
  • The Debt to FCF ratio of COLL is 2.79, which is a good value as it means it would take COLL, 2.79 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 2.79, COLL belongs to the best of the industry, outperforming 91.19% of the companies in the same industry.
  • A Debt/Equity ratio of 2.71 is on the high side and indicates that COLL has dependencies on debt financing.
  • COLL has a worse Debt to Equity ratio (2.71) than 78.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF 2.79
Altman-Z 1.34
ROIC/WACC0.99
WACC9.22%
COLL Yearly LT Debt VS Equity VS FCFCOLL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

  • COLL has a Current Ratio of 1.36. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
  • COLL's Current ratio of 1.36 is on the low side compared to the rest of the industry. COLL is outperformed by 73.58% of its industry peers.
  • COLL has a Quick Ratio of 1.27. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
  • COLL has a Quick ratio of 1.27. This is in the lower half of the industry: COLL underperforms 68.39% of its industry peers.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 1.27
COLL Yearly Current Assets VS Current LiabilitesCOLL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. COLL Growth Analysis

3.1 Past

  • COLL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.66%, which is quite good.
  • Measured over the past years, COLL shows a very strong growth in Earnings Per Share. The EPS has been growing by 57.90% on average per year.
EPS 1Y (TTM)15.66%
EPS 3Y137.06%
EPS 5Y57.9%
EPS Q2Q%15.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.92%

3.2 Future

  • COLL is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.39% yearly.
  • The Revenue is expected to grow by 1.28% on average over the next years.
EPS Next Y2.08%
EPS Next 2Y-5.87%
EPS Next 3Y-12.23%
EPS Next 5Y-2.39%
Revenue Next Year3.9%
Revenue Next 2Y-2.3%
Revenue Next 3Y-2.41%
Revenue Next 5Y1.28%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
COLL Yearly Revenue VS EstimatesCOLL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
COLL Yearly EPS VS EstimatesCOLL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 6

More info and screens

Find the best growth stocksShow best growing peers

8

4. COLL Valuation Analysis

4.1 Price/Earnings Ratio

  • COLL is valuated cheaply with a Price/Earnings ratio of 4.99.
  • Based on the Price/Earnings ratio, COLL is valued cheaply inside the industry as 95.85% of the companies are valued more expensively.
  • COLL's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.45.
  • Based on the Price/Forward Earnings ratio of 4.89, the valuation of COLL can be described as very cheap.
  • 95.34% of the companies in the same industry are more expensive than COLL, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.65, COLL is valued rather cheaply.
Industry RankSector Rank
PE 4.99
Fwd PE 4.89
COLL Price Earnings VS Forward Price EarningsCOLL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • COLL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. COLL is cheaper than 97.93% of the companies in the same industry.
  • COLL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. COLL is cheaper than 97.41% of the companies in the same industry.
Industry RankSector Rank
P/FCF 4.09
EV/EBITDA 4.1
COLL Per share dataCOLL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of COLL may justify a higher PE ratio.
  • COLL's earnings are expected to decrease with -12.23% in the coming years. This may justify a cheaper valuation.
PEG (NY)2.39
PEG (5Y)0.09
EPS Next 2Y-5.87%
EPS Next 3Y-12.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. COLL Dividend Analysis

5.1 Amount

  • COLL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

COLL Fundamentals: All Metrics, Ratios and Statistics

COLLEGIUM PHARMACEUTICAL INC

NASDAQ:COLL (3/10/2026, 9:45:58 AM)

37.24

-0.03 (-0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners122.15%
Inst Owner Change1.08%
Ins Owners2%
Ins Owner Change1.51%
Market Cap1.18B
Revenue(TTM)N/A
Net Income(TTM)58.44M
Analysts81.67
Price Target54.74 (46.99%)
Short Float %15.42%
Short Ratio10.86
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.9%
Min EPS beat(2)1.88%
Max EPS beat(2)7.92%
EPS beat(4)4
Avg EPS beat(4)6.15%
Min EPS beat(4)1.88%
Max EPS beat(4)12.85%
EPS beat(8)7
Avg EPS beat(8)12.99%
EPS beat(12)9
Avg EPS beat(12)-15.06%
EPS beat(16)10
Avg EPS beat(16)-21.97%
Revenue beat(2)2
Avg Revenue beat(2)5.22%
Min Revenue beat(2)1.9%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.8%
Revenue beat(12)6
Avg Revenue beat(12)0.28%
Revenue beat(16)8
Avg Revenue beat(16)-3.75%
PT rev (1m)0.94%
PT rev (3m)14.67%
EPS NQ rev (1m)0.07%
EPS NQ rev (3m)-5.95%
EPS NY rev (1m)0.03%
EPS NY rev (3m)-1.1%
Revenue NQ rev (1m)0.1%
Revenue NQ rev (3m)-0.35%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)-0.12%
Valuation
Industry RankSector Rank
PE 4.99
Fwd PE 4.89
P/S 1.56
P/FCF 4.09
P/OCF 4.06
P/B 4.3
P/tB N/A
EV/EBITDA 4.1
EPS(TTM)7.46
EY20.03%
EPS(NY)7.62
Fwd EY20.45%
FCF(TTM)9.11
FCFY24.47%
OCF(TTM)9.16
OCFY24.6%
SpS23.84
BVpS8.66
TBVpS-18.77
PEG (NY)2.39
PEG (5Y)0.09
Graham Number38.12
Profitability
Industry RankSector Rank
ROA 3.64%
ROE 21.27%
ROCE 13.6%
ROIC 9.1%
ROICexc 12.09%
ROICexgc N/A
OM 20.74%
PM (TTM) 7.72%
GM 57.22%
FCFM 38.21%
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
ROICexc(3y)16.99%
ROICexc(5y)14.94%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)16.56%
ROCE(5y)13.94%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y15.58%
ROICexc growth 5YN/A
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF 2.79
Debt/EBITDA 1.94
Cap/Depr 0.72%
Cap/Sales 0.21%
Interest Coverage 2.17
Cash Conversion 75.92%
Profit Quality 495.01%
Current Ratio 1.36
Quick Ratio 1.27
Altman-Z 1.34
F-Score7
WACC9.22%
ROIC/WACC0.99
Cap/Depr(3y)142.93%
Cap/Depr(5y)207.67%
Cap/Sales(3y)41.34%
Cap/Sales(5y)49.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.66%
EPS 3Y137.06%
EPS 5Y57.9%
EPS Q2Q%15.25%
EPS Next Y2.08%
EPS Next 2Y-5.87%
EPS Next 3Y-12.23%
EPS Next 5Y-2.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.92%
Revenue Next Year3.9%
Revenue Next 2Y-2.3%
Revenue Next 3Y-2.41%
Revenue Next 5Y1.28%
EBIT growth 1Y-18.86%
EBIT growth 3Y89.16%
EBIT growth 5YN/A
EBIT Next Year157.33%
EBIT Next 3Y31.88%
EBIT Next 5Y18.85%
FCF growth 1Y8.55%
FCF growth 3Y25.98%
FCF growth 5Y56.88%
OCF growth 1Y8.67%
OCF growth 3Y25.54%
OCF growth 5Y49.12%

COLLEGIUM PHARMACEUTICAL INC / COLL FAQ

What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?

ChartMill assigns a fundamental rating of 5 / 10 to COLL.


What is the valuation status for COLL stock?

ChartMill assigns a valuation rating of 8 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.


What is the profitability of COLL stock?

COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 7 / 10.


Can you provide the financial health for COLL stock?

The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 4 / 10.